


**EyeOnAccess Academy**

# Managing Access to Anti-VEGF Therapies:

An Educational Series for  
Retina Specialist, Clinical Decision-makers, and staff



**REGENERON<sup>®</sup>**

All trademarks are property of their respective owners.

© 2025 Regeneron Pharmaceuticals Inc. All rights reserved. 06/2025 US.OPH.25.06.0005



**GET STARTED**

# Program Introduction

- As anti-VEGF therapies have revolutionized care for patients timely and efficient clinic access to, and reimbursement for, these therapies is critical<sup>1</sup>
- This program was designed to provide important information concisely delivered to help ensure efficient access to therapies in a dynamic anti-VEGF market landscape
  - Streamlined, self-driven modules are designed for engagement in short intervals of time
  - At the end of each module, a question is included to assess knowledge about a key concept covered within the curriculum



BACK



NEXT

DME = diabetic macular edema; DR = diabetic retinopathy; nAMD = neovascular age-related macular degeneration; VEGF: vascular endothelial growth factor.

1. Castillo A. Anti-VEGF, money, and your practice. *Ophthalmology Management*. August 1, 2017. Accessed November 23, 2024.

<https://ophthalmologymanagement.com/issues/2017/august/anti-vegf-money-and-your-practice/>.

**REGENERON**®

FOR INFORMATIONAL PURPOSES ONLY

# Program Objectives



Enhance knowledge of retina business and treatment models to help improve overall access to anti-VEGF therapies



Provide education to inform on potential patient barriers in the treatment for retinal disease



Deliver critical insights to help navigate impact of market changes on patient care



BACK



NEXT

# Program Components

- The program is comprised of several intuitive, self-study micromodules that cover a range of high-relevance topics for retina clinics
- Content was developed to be informative without requiring substantial investment of time; consumable across one or multiple viewings
- These modules are structured to enable targeted review of specific topics as needed; however, each user is encouraged to review all modules for the most comprehensive experience



BACK


## Retina Clinic Access Considerations for Anti-VEGFs



NEXT



**Module 1:**  
Overview of treatments and reimbursement considerations within the anti-VEGF landscape



**Module 2:**  
Drug acquisition in the clinic




**Module 3:**  
Considerations for the use of anti-VEGF agents in the clinic

**REGENERON®**


FOR INFORMATIONAL PURPOSES ONLY

# Program Components (cont'd)

## Understanding and Managing Patient Access to Therapy



**Module 4:** Managing patient access to therapy



**Module 5:** Benefit design and medical policy impact on access for patients


BACK

NEXT

**REGENERON®**

FOR INFORMATIONAL PURPOSES ONLY

# Micromodule Navigation Overview



# You Are Ready to Get Started!

- Now that you have completed the introductory module and have learned about the program curriculum and navigation, you are ready to move on to Module 1 at [[www.EyeOnAccessAcademy.com](http://www.EyeOnAccessAcademy.com)]!
- If you have questions or wish to discuss any feedback on this program, please reach out to your Regeneron contact or use this email: [oph.marketaccess@Regeneron.com](mailto:oph.marketaccess@Regeneron.com)



BACK



**REGENERON**®

FOR INFORMATIONAL PURPOSES ONLY